Oncogenic Long Noncoding RNAs in Prostate Cancer, Osteosarcoma, and Metastasis.
Aishah Al-ShehriJolanta U WeaverPublished in: Biomedicines (2023)
Prostate cancer (PC) is a common malignancy and is one of the leading causes of cancer-related death in men worldwide. Osteosarcoma (OS) is the most common bone cancer, representing 20-40% of all bone malignancy cases. Cancer metastasis is a process by which malignant tumor cells detach from the primary tumor site via a cascade of processes and migrate to secondary sites through the blood circulation or lymphatic system to colonize and form secondary tumors. PC has a specific affinity to the bone based on the "seed and soil" theory; once PC reach the bone, it becomes incurable. Several studies have identified long noncoding RNAs (lncRNAs) as potential targets for cancer therapy or as diagnostic and prognostic biomarkers. The dysregulation of various lncRNAs has been found in various cancer types, including PC, OS, and metastasis. However, the mechanisms underlying lncRNA oncogenic activity in tumor progression and metastasis are extremely complex and remain incompletely understood. Therefore, understanding oncogenic lncRNAs and their role in OS, PC, and metastasis and the underlying mechanism may help better manage and treat this malignancy. The aim of this review is to summarize current knowledge of oncogenic lncRNAs and their involvement in PC, OS, and bone metastasis.
Keyphrases
- prostate cancer
- bone mineral density
- papillary thyroid
- cancer therapy
- soft tissue
- squamous cell
- bone regeneration
- transcription factor
- bone loss
- healthcare
- drug delivery
- squamous cell carcinoma
- network analysis
- risk assessment
- body composition
- poor prognosis
- mass spectrometry
- childhood cancer
- genome wide analysis
- human health
- middle aged
- case control